SHIELD THERAPEUTICS

SHIELD THERAPEUTICS

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

Shield Therapeutics_logo

Industry:
Company

Founded:
2008

Address:
Northern Design Centre, Gateshead, United Kingdom Zipcode NE8 3DF

Country:
United Kingdom

Phone:
44 1915 118 500

Company Size Range:
51 - 200
Current Employees:
25
Total Employees:
72

Market Cap:
97.67M
Total Revenue:
719k
Total Assets:
36.32M
Total Cash:
4.14M

Subsidiaries: Phosphate Therapeutics Ltd. · Shield Holdings AG · Phosphate Therapeutics


Key Executives
Name Title Pay Year Born
Mr. Timothy William Watts CEO & Director N/A 1958(62 years old)
Mr. Hans-Peter Rudolf Chief Financial Officer N/A N/A
Fleur Wood Director of Investor Relations N/A N/A
Ms. Lucy Huntington-Bailey Gen. Counsel & Company Sec. N/A N/A
Ms. Suzanne Wood Group HR Director N/A N/A
Mr. Paul Steckler Chief Commercial Officer N/A N/A
Ms. Carol Akinola Head of Pharmacovigilance & Medical Information N/A N/A



Financial & Stock
Exchange LSE. Currency in GBp. Market state POSTPOST
According to Shield Therapeutics's financial reports the company's revenue in 2019 were 719k an increase(-93.46%) over the years 2018 revenue that were of 11.88M. In 2019 the company's total earnings were -8.8M while total earnings in 2018 were -1.79M( +700%).
Company's stock symbol is STX.L. Lastest price : 45.25. Total volume :881.69k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.shieldtherapeutics.com

  • Host name: server.ur-gold-1.co.uk
  • IP address: 46.37.186.163
  • Location: Hartlepool United Kingdom
  • Latitude: 54.7
  • Longitude: -1.25
  • Timezone: Europe/London
  • Postal: TS26

Loading ...
Loading ...


More informations about "Shield Therapeutics" on Search Engine

Shield Therapeutics | Feraccru | Pharmaceutical Company

Shieldtherapeutics.com Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.

Shield Therapeutics | Feraccru | Pharmaceutical Company

Shieldtherapeutics.com Investors | Why invest in Shield Therapeutics?

Shield Therapeutics | Feraccru | Pharmaceutical Company

Shieldtherapeutics.com About Shield Therapeutics | Specialty Pharmaceutical Company

Shield Therapeutics | Feraccru | Pharmaceutical Company

Shieldtherapeutics.com Treatment of Iron Deficiency Anaemia ... - Shield Therapeutics

Shield Therapeutics | Feraccru | Pharmaceutical Company

Shieldtherapeutics.com Lead Products | PT20 | Feraccru | Shield Therapeutics

Shield Therapeutics | Feraccru | Pharmaceutical Company

Shieldtherapeutics.com Management and Board of Directors | Shield Therapeutics

Shield Therapeutics | Feraccru | Pharmaceutical Company

Shieldtherapeutics.com Contact Shield Therapeutics Pharmaceutical Company

Shield Therapeutics | Feraccru | Pharmaceutical Company

Shieldtherapeutics.com Latest News about Feraccru and Shield Therapeutics

Shield Therapeutics | Feraccru | Pharmaceutical Company

Shieldtherapeutics.com PT20 | Treatment for hyperphosphatemia - Shield Therapeutics

Shield Therapeutics | Feraccru | Pharmaceutical Company

Shieldtherapeutics.com Investor and Scientific Events | Shield Therapeutics

Shield Therapeutics | Feraccru | Pharmaceutical Company

Shieldtherapeutics.com Business and Trading Update | Shield Therapeutics

SHIELD THERAPEUTICS PLC ORD 1.5 (STX.L) Stock Price, News

Finance.yahoo.com Investors Who Bought Shield Therapeutics (LON:STX) Shares Three Years Ago Are Now Down 45% As an investor its worth striving to ensure your overall portfolio beats the market average. But if you...

STX Share Forecast, Price & News (Shield Therapeutics)

Marketbeat.com Some companies that are related to Shield Therapeutics include The Supreme Cannabis (FIRE), The Green Organic Dutchman (TGOD), ESSA Pharma (EPI), Diurnal Group (DNL), Venture Life Group (VLG), WeedMD (WMD), Delta 9 Cannabis (NINE), Science in Sport (SIS), Acerus Pharmaceuticals (ASP), The Flowr (FLWR), BioSyent (RX), Medexus Pharmaceuticals (MDP), Viridium Pacific Group (VIR), Cipher …

Shield Therapeutics - Crunchbase Company Profile & Funding

Crunchbase.com Shield Therapeutics is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. During 2011 Shield will be commencing global pivotal Phase III studies of its lead asset, ST10-021, for the treatment of iron

Shield Therapeutics Plc Share Chat - Chat About STX Shares

Uk.advfn.com 24 rows · Aug 06, 2020 · Shield Therapeutics Share Chat (STX) Follow STX. Buy. Sell. Share Name …

Shield Therapeutics PLC raises £25mln and sets sail for the US

Proactiveinvestors.co.uk Mar 22, 2021 · What Shield does Shield Therapeutics PLC (LON:STX) is a speciality pharmaceutical company focused on the development and commercialisation of late-stage pharmaceuticals. Its lead asset, Feraccru...

Shield Therapeutics - Fortified for growth | Edison

Edisongroup.com Feb 19, 2019 · Shield Therapeutics is a commercial-stage speciality pharmaceutical company based in the United Kingdom. Its primary focus is commercialisation of Feraccru, approved by the EMA for the treatment of iron deficiency, which is associated with many chronic illnesses and nutritional deficiencies.

Shield Therapeutics | Share Price, Company News & Analysis

Edisongroup.com Shield Therapeutics is a commercial-stage pharmaceutical company. Its proprietary product, Feraccru, is approved by the EMA and FDA for the treatment of iron deficiency. Outside of the US Feraccru is marketed through partners Norgine, AOP Orphan and Ewopharma.

Shield Therapeutics - Accrufer coming to America | Edison

Edisongroup.com Shield Therapeutics is a commercial-stage pharmaceutical company. Its proprietary product, Feraccru, is approved by the EMA and FDA for the treatment of iron deficiency. Feraccru is marketed through partners Norgine, AOP Orphan and Ewopharma.

SHIELD THERAPEUTICS PLC STX Trade recap - Stock | London

Londonstockexchange.com SHIELD THERAPEUTICS PLC STX Trade recap - Search stock, chart, recent trades, company information, trading information, company news, fundamentals

Shield Therapeutics PLC fundraise totals £29.2mln as open

Proactiveinvestors.co.uk Mar 18, 2021 · Shield Therapeutics (LON:STX) Presenting at the Proactive One2One Virtual Forum 8th April 2021 Shield is a de-risked commercial stage, pharmaceutical company …

Chinese Drugmaker Aosaikang to Bring in Oral Iron

Yicaiglobal.com (Yicai Global) Jan. 8 -- Chinese medicine manufacturer Beijing Aosaikang Pharmaceutical inked a licensing agreement today with UK-based specialty pharma firm Shield Therapeutics to obtain the exclusive right to develop, produce and market in China a new-style oral iron supplement which the British drugmaker developed, Aosaikang said in a statement.

Shield Therapeutics PLC, STX:LSE summary - FT.com

Markets.ft.com Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron de ficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.

Shield Therapeutics PLC to raise £25mln for US launch of

Proactiveinvestors.co.uk Feb 27, 2021 · Shield Therapeutics PLC has successfully raised £25mln through a share placing and subscription at 30p to launch and market its Accrufer iron deficiency treatment in …

Shield Therapeutics Share Price. STX - Stock Quote, Charts

Uk.advfn.com Jul 06, 2020 · Shield Therapeutics share price data is direct from the London Stock Exchange Stake Launches Epic Million Dollar Race For April Stake.com, the leader in …

Shield Therapeutics (LON:STX) : US Opportunity Awaits

Proactiveinvestors.co.uk Mar 11, 2021 · Shield Therapeutics (LON:STX) Presenting at the Proactive One2One Virtual Forum 8th April 2021 Shield is a de-risked commercial stage, pharmaceutical company …

Shield Therapeutics PLC (LSE:STX) | RNS | Shield

Proactiveinvestors.com London, UK, 30 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that Tim Watts, Chief Executive Officer, will present at the Proactive One2One ...

Shield Thera Share Chat. Chat About STX Shares - Stock

Lse.co.uk Shield Thera Share Chat. Chat About STX Shares - Stock Quote, Charts, Trade History, Share Chat, Financial Terms Glossary.

Shield Therapeutics PLC (LSE:STX) | RNS | Shield

Proactiveinvestors.com Mar 03, 2021 · Shield Therapeutics plc ("Shield Therapeutics" or the "Company") Investor Presentation London, UK - 3 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company, announces that it will provide a live presentation on Tuesday 9 March 2021 at 4.00pm covering the recent £25m fundraise and Open Offer to raise up to £4.2m and the US market …

Shield Therapeutics : Feraccru®/Accrufer® publications

Marketscreener.com Shield Therapeutics plc ('Shield' or the 'Group' or the 'Company') Feraccru®/Accrufer ® publications. London, UK, 3 June 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), notes the recent publication of two papers concerning Feraccru ® /Accrufer ®.

Shield Therapeutics : IMC Presentation | MarketScreener

Marketscreener.com Overview of Shield Therapeutics: Revenue Generating Pharmaceutical Company Focused on the Treatment of Iron Deficiency • AIM-listed biotech company (STX.L) - …

STX:London Stock Quote - Shield Therapeutics PLC

Bloomberg.com Shield Therapeutics plc is a specialty pharmaceutical company focused on the development and commercialization of secondary care-focused pharmaceuticals.

Shield Therapeutics : Proactive Investor 1-2-1 Forum

Marketscreener.com Apr 09, 2021 · Shield Therapeutics plc published this content on 09 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and …

Shield Therapeutics : Result of General Meeting & Open

Marketscreener.com Shield Therapeutics plc LEI: 213800G74QWY15FC3W71. Commenting on the Open Offer take up, Tim Watts, CEO of Shield Therapeutics plc, said: " On behalf of the Board, I would like to acknowledge the strong support shown by the Company's shareholders and a number of new institutional investors for the equity financing announced last month.

SHIELD THERAPEUTICS PLC (SHIEF) Stock Price, News, Quote

Finance.yahoo.com Find the latest SHIELD THERAPEUTICS PLC (SHIEF) stock quote, history, news and other vital information to help you with your stock trading and investing.

Shield Therapeutics Company Profile - Office Locations

Craft.co Jan 10, 2020 · Shield Therapeutics is an independent specialty pharmaceutical company focused on the development and commercialization of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. The Company’s key products are Feraccru and PT20, one commercially available and one late-stage pharmaceutical for the ...

Shield Therapeutics : The latest share price | Sharecast.com

Sharecast.com *A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: Obtains access to the information in a personal capacity;

SHIELD THERAPEUTICS PLC : Shareholders Board Members

Marketscreener.com Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.

Shield Therapeutics : Shares Magazine/AJ Bell Webinar

Marketscreener.com Investor Presentation Shares Magazine/AJ Bell webinar. 20 January 2021. Disclaimer. These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of providing background information on the Company, its business and the industry in which it operates.

Shield Therapeutics : Business and trading update

Marketscreener.com Shield Therapeutics plc ('Shield' or the 'Group' or the 'Company') London, UK, 1 May 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel oral iron treatment, provides a business and unaudited trading update. ...

Shield Therapeutics - Next step a US partnering deal | Edison

Edisongroup.com May 04, 2020 · Shield Therapeutics (STX) has provided an updated trading statement ahead of FY19 results, expected at the end of May. In its January trading update, STX had guided to FY19 revenues of £2.9m. However, this has been revised down to £0.7m with repayment of the €2.5m Norgine milestone. In Europe, Feraccru has continued to grow during Q120 in its launched countries (the UK and Germany), …

Ferric maltol - Shield Therapeutics - AdisInsight

Adisinsight.springer.com 08 Jan 2020 Shield Therapeutics entered into license agreement with Beijing Aosaikang Pharmaceutical in China, Hong Kong, Macau and Taiwan 22 Oct 2019 Efficacy data from a phase IIIb trial in Iron deficiency anaemia released by Shield Therapeutics

Shield Therapeutics PLC (LSE:STX) | RNS | Shield

Proactiveinvestors.com About Shield Therapeutics plc. Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield (@shieldtx) | Twitter

Twitter.com The latest tweets from @shieldtx

Shield Therapeutics : Investor Presentation | Markets Insider

Markets.businessinsider.com Mar 03, 2021 · Shield Therapeutics NewsMORE. Shield Therapeutics : Total Voting Rights Update. Investegate 6d: Shield Therapeutics : Block Listing 6 Monthly Return. Investegate 6d:

Shield Therapeutics (AIM:STX) - Share price, News

Simplywall.st Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. More Details. Rewards. Trading at 98.5% below our estimate of its fair value. Earnings are forecast to grow 45.84% per year.

SHIELD THERAPEUTICS PLC STX Stock | London Stock Exchange

Londonstockexchange.com SHIELD THERAPEUTICS PLC STX Company page - Search stock, chart, recent trades, company information, trading information, company news, fundamentals

Shield Therapeutics PLC (LSE:STX) | RNS | Shield

Proactiveinvestors.com Dec 22, 2020 · Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive... Proactive Research analyst Emma Ulker says further conclusions from Shield Therapeutics' (LON:STX) analysis of data from the AEGIS-H2H study are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru.

Shield Therapeutics plc | LinkedIn

Linkedin.com Shield Therapeutics plc | 2,022 followers on LinkedIn. Helping patients become people again | Shield is a de-risked commercial stage, pharmaceutical company delivering innovative specialty ...

Shield Therapeutics Stock Forecast: up to 54.369 GBX

Walletinvestor.com Shield Therapeutics plc () Stock Market info Recommendations: Buy or sell Shield Therapeutics stock? London Stock Market & Finance report, prediction for the future: You'll find the Shield Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data Shield Therapeutics's STX shares and potentially its market environment have been in bearish cycle last 12 ...

Shield Therapeutics plc (LON:STX) Insider Purchases £

Theenterpriseleader.com Mar 08, 2021 · Shield Therapeutics plc (LON:STX) insider Hans-Peter Hasler purchased 200,000 shares of the company’s stock in a transaction on Wednesday, March 3rd. The shares were bought at an average cost of GBX 37 ($0.48) per share, with a total value of £74,000 ($96,681.47). Hans-Peter Hasler also recently made the following trade(s): On Friday, March 5th, Hans-Peter […]

Pharmacy resources | Prime Therapeutics

Primetherapeutics.com Sep 09, 2020 · Blue Cross and Blue Shield of Kansas – 877.893.8485. Blue Cross and Blue Shield of Montana – 866.590.3012. Horizon Blue Cross Blue Shield of New Jersey – 877.686.6875. Blue Cross and Blue Shield of North Carolina – 888.274.5186. Blue Cross and Blue Shield of Oklahoma – 877.353.0992. Blue Cross Blue Shield of Wyoming – 800.424.7094

Turning Point Therapeutics, Inc. Privacy Shield Data

Tptherapeutics.com Update on Privacy Shield: In recognition of recent EU court and regulator decisions, Turning Point no longer relies on the EU-U.S. and Swiss-U.S. Privacy Shield ...